0

The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium Tuberculosis in Hypoxia at Neutral pH

Angelo Iacobino, Federico Giannoni, Manuela Pardini, Giovanni Piccaro, Lanfranco Fattorini

Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00273-19.

PMID: 31010861

Abstract:

The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP168828588 Sutezolid Sutezolid 168828-58-8 Price
qrcode